Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 6/20 | 0.57 |
| ▸ | TOP2A | P11388 | 7/20 | 0.53 |
| ▸ | TOP2B | Q02880 | 7/20 | 0.53 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.52 |
| ▸ | DRD1 | P21728 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.51 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.51 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.50 |
| ▸ | LMNA | P02545 | 3/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.48 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27789261 | 0.94 | DPP4 (0.52) | DPP4TOP2ATOP2BCHRM2DRD1 | |
| SCHEMBL27344629 | 0.90 | DPP4 (0.48) | DPP4TOP2ATOP2BCHRM2DRD1 | |
| SCHEMBL23498281 | 0.89 | DPP4 (0.49) | DPP4TOP2ATOP2BCHRM2DRD1 | |
| SCHEMBL6215444 | 0.88 | DPP4 (0.52) | DPP4TOP2ATOP2BCHRM2DRD1 | |
| SCHEMBL5142702 | 0.88 | DPP4 (0.58) | DPP4TOP2ATOP2BCHRM2DRD1 | |
| SCHEMBL9437304 | 0.88 | TOP2A (0.58) | DPP4TOP2ATOP2BCHRM2DRD1 | |
| SCHEMBL17270378 | 0.87 | DPP4 (0.48) | DPP4TOP2ATOP2BCHRM2DRD1 | |
| SCHEMBL9097293 | 0.86 | DPP4 (0.47) | DPP4TOP2ATOP2BCHRM2DRD1 | |
| SCHEMBL501153 | 0.86 | DPP4 (0.47) | DPP4TOP2ATOP2BCHRM2DRD1 | |
| SCHEMBL9014149 | 0.86 | DPP4 (0.47) | DPP4TOP2ATOP2BCHRM2DRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 442 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114989165-A | Compound or composition for resisting retention bacteria and biofilm bacteria and application thereof | 青岛大学附属医院 | 2022-09-02 | — | — | CN | claimed |
| US-20110136855-A1 | GEMIFLOXACIN PROCESS AND POLYMORPHS | HETERO DRUGS LIMITED (IN) | 2011-06-09 | — | — | US | claimed |
| US-20080293760-A1 | Gemifloxacin Process and Polymorphs | HETERO DRUGS LIMITED (IN) | 2008-11-27 | — | — | US | claimed |
| EP-1891037-A1 | GEMIFLOXACIN PROCESS AND POLYMORPHS | Hetero Drugs Limited (IN) | 2008-02-27 | — | — | EP | claimed |
| WO-2006134608-A1 | GEMIFLOXACIN PROCESS AND POLYMORPHS | HETERO DRUGS LIMITED (IN) | 2006-12-21 | — | — | WO | claimed |
| EP-0160578-B1 | 1,8-NAPHTHYRIDINE DERIVATIVES | DAIICHI SEIYAKU CO., LTD. (JP) | 1989-11-23 | — | — | EP | claimed |
| CN-1003236-B | Preparation method of 6, 7-disubstituted-1-cyclopropyl-1, 4-dihydro-4-oxo-1, 8-naphthyridine-3-carboxylic acid | 拜尔公司 | 1989-02-08 | — | — | CN | claimed |
| US-4663457-A | BACTERICIDES | WARNER-LAMBERT COMPANY (US) | 1987-05-05 | — | — | US | claimed |
| EP-0160578-A1 | 1,8-Naphthyridine derivatives | DAIICHI SEIYAKU CO., LTD. (JP) | 1985-11-06 | — | — | EP | claimed |
| JP-60197686-A | — | — | None | — | — | JP | disclosed |
| EP-4073062-B1 | FUNCTIONALIZED HETEROCYCLIC COMPOUNDS AS MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) | RYVU THERAPEUTICS S A (PL) | 2026-04-29 | — | — | EP | disclosed |
| US-20250313561-A1 | NEXT-GENERATION MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) | RYVU THERAPEUTICS S A (PL) | 2025-10-09 | — | — | US | disclosed |
| US-12344606-B2 | Next-generation modulators of stimulator of interferon genes (STING) | Ryvu Therapeutics S.A. (PL) | 2025-07-01 | — | — | US | disclosed |
| CN-114989165-B | Compound or composition for resisting persistant bacteria and biomembrane bacteria and application thereof | 青岛大学附属医院 | 2024-11-08 | — | — | CN | disclosed |
| US-4571396-A | Antibacterial agents | WARNER-LAMBERT COMPANY (US) | 1986-02-18 | — | — | US | disclosed |
| EP-0160578-A1 | 1,8-Naphthyridine derivatives | DAIICHI SEIYAKU CO., LTD. (JP) | 1985-11-06 | — | — | EP | disclosed |
| EP-0159174-A2 | Substituted naphthyridine-, quinoline- and benzoxazine- carboxylic acids as antibacterial agents and processes for their production | WARNER-LAMBERT COMPANY (US) | 1985-10-23 | — | — | EP | disclosed |
| JP-S60197686-A | 1,8-NAPHTHYRIDINE DERIVATIVE | DAI ICHI SEIYAKU CO LTD | 1985-10-07 | — | — | JP | disclosed |
| EP-0153828-A2 | 1-cyclopropyl-1, 4-dihydro-6-fluoro-4-oxo-1, 8-naphthyridine-3-carboxylic acids; their derivatives and a process for preparing the compounds | WARNER-LAMBERT COMPANY (US) | 1985-09-04 | — | — | EP | disclosed |
| EP-0153163-A2 | 7-Substituted-1-cyclopropyl-6,8-difluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acids; 7-substituted-1-cyclopropyl-1,4-dihydro-6-fluoro-4-oxo-1,8-naphthyridine-3-carboxylic acids; their derivatives; and a process for preparing the compounds | WARNER-LAMBERT COMPANY (US) | 1985-08-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12344606-B2 | Next-generation modulators of stimulator of interferon genes (STING) | STING1, IRF3, CGAS | DPP4 4253/4885TOP2A 597/4885TOP2B 616/4885 |
| US-20110136855-A1 | GEMIFLOXACIN PROCESS AND POLYMORPHS | ABCB11, NRAS, UGT1A6 | DPP4 709/4885TOP2A 299/4885TOP2B 534/4885 |
| US-20250313561-A1 | NEXT-GENERATION MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) | STING1, IRF3, CGAS | DPP4 4253/4885TOP2A 597/4885TOP2B 616/4885 |
| US-20080293760-A1 | Gemifloxacin Process and Polymorphs | ABCB11, UGT1A6, CYP2B6 | DPP4 544/4885TOP2A 339/4885TOP2B 505/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.